Regular Article
Decreased Expression of Adenosine Kinase in Streptozotocin-Induced Diabetes Mellitus Rats

https://doi.org/10.1006/abbi.1999.1548Get rights and content

Abstract

Adenosine has been implicated as an important endogenous regulator of various tissue functions. In diabetes, the responsiveness of several tissues to adenosine is altered. The aim of this study was to investigate the activities of enzymes metabolizing adenosine in tissues of diabetic rats. The cytosolic activity (Vmax) of adenosine kinase (AK) was decreased by 50% in the kidney and by 40% in the heart and liver of diabetic rats. A decrease in the Vmax of AK in diabetic tissues was not associated with a change in the Km for adenosine. Evaluation of AK gene transcript status showed significantly lower levels of AK mRNA in diabetic tissues as compared to normal tissues. In diabetic kidneys, the level of AK gene transcript was lowered by 50% on first day after streptozotocin administration, and these reduced levels were sustained declined during the next 10 days. Smaller changes in AK gene transcript levels were observed in the heart and liver than in the kidney. The cytosolic activities of 5′-nucleotidase, AMP deaminase, and adenosine deaminase were unchanged in kidney, heart, and liver of diabetic rats. These results suggest that the turnover of the AMP-adenosine metabolic cycle might be impaired in diabetic tissues due to the reduced activity of adenosine kinase.

References (40)

  • A.S. Krolewski et al.

    Am. J. Med.

    (1985)
  • G.L. Stiles

    J. Biol. Chem.

    (1992)
  • J.A. Gasser et al.

    Cell Signal

    (1993)
  • S. Angielski et al.

    Biochem. Biophys. Res. Commun.

    (1990)
  • T. Pawelczyk et al.

    Biochim. Biophys. Acta

    (1992)
  • O.H. Lowry et al.

    J. Biol. Chem.

    (1951)
  • J. Stepinski et al.

    Kidney. Int.

    (1996)
  • J.M. Webster et al.

    Biochim. Biophys. Acta.

    (1996)
  • T. McNally et al.

    Biochem. Biophys. Res. Commun.

    (1997)
  • C.E. Mogensen et al.

    Diabetologia

    (1980)
  • M. Epstein et al.

    Hypertension

    (1992)
  • H. Osswald et al.

    Int. J. Biochem.

    (1980)
  • D. Pawlowska et al.

    Am. J. Physiol.

    (1987)
  • M. Szczepanska-Konkel et al.

    Contrib. Nephrol.

    (1991)
  • J.P. Headrick et al.

    Am. J. Physiol.

    (1991)
  • J.P. Headrick et al.

    Cardiovasc. Res.

    (1996)
  • W.S. Spielman et al.

    Hypertension

    (1991)
  • D.R. Wagner et al.

    Circulation

    (1994)
  • J.M. Lowenstein et al.
  • Cited by (48)

    • Adenosine kinase: An epigenetic modulator in development and disease

      2021, Neurochemistry International
      Citation Excerpt :

      As a regulator of adenosine, maladaptive changes in ADK expression have been implicated in a number of pathologies, including epilepsy, brain injury, stroke, diabetes, and cancer (Boison, 2013; Boison and Yegutkin, 2019). Initially, the role of ADK in those pathologies has been linked to its role as regulator of the tissue tone of adenosine, which determines the degree of adenosine receptor activation (Aronica et al., 2011; Giglioni et al., 2008; Li et al., 2008a; Masino et al., 2011; Pawelczyk et al., 2000; Saitoh et al., 2004; Sakowicz-Burkiewicz et al., 2006; Tsuchiya et al., 2012). However, ADK is also a well-characterized key regulator of the transmethylation pathway (Bjursell et al., 2011; Boison et al., 2002; Moffatt et al., 2002; Williams-Karnesky et al., 2013; Xu et al., 2017a, 2017b), which suggests additional functions of ADK beyond its role as a regulator of adenosine receptor activation.

    • “Adenosine an old player with new possibilities in kidney diseases”: Preclinical evidences and clinical perspectives

      2021, Life Sciences
      Citation Excerpt :

      Induction of diabetes resulted in reduced activity and transcript levels of AK in kidneys of rats. Moreover these changes were consistent after 5 and 10 days of streptozotocin administration in these rats [99]. However, this study could not find any difference in ADA activity in diabetic rat kidneys.

    • Adenosine kinase and cardiovascular fetal programming in gestational diabetes mellitus

      2020, Biochimica et Biophysica Acta - Molecular Basis of Disease
    • Glioma progression in diabesity

      2019, Molecular Aspects of Medicine
      Citation Excerpt :

      On the other hand, a profound reduction in the plasma insulin concentration in streptozotocin-induced diabetes results in elevated ADAs activity in these tissues (Fulzele et al., 2015; Rutkiewicz and Gorski, 1990). Also, AK is decreased in the kidney of diabetic rats leading to a local increase in adenosine concentration (Pawelczyk et al., 2000). All together these studies suggest that the local concentration of adenosine may be affected by the plasma concentration of insulin and its biological actions on ADAs and AK activity in target organs and tissues (Fulzele et al., 2015).

    • Adenosine contribution to normal renal physiology and chronic kidney disease

      2017, Molecular Aspects of Medicine
      Citation Excerpt :

      Thus CD73 would be useful as a marker of CKD progression in the clinic. Other studies on adenosine metabolizing enzymes found that the expression of ecto-adenosine kinase (adenosine → AMP) was significantly lower in diabetic rat kidney (Pawelczyk et al., 2000; Sakowicz and Pawelczyk, 2002). Using different experimental approaches, it was suggested that increased adenosine and signaling is a common event in the pathogenesis of non-diabetic chronic kidney disease (Dai et al., 2011).

    • Adenosine receptors and diabetes: Focus on the A<inf>2B</inf> adenosine receptor subtype

      2015, Pharmacological Research
      Citation Excerpt :

      Accordingly the inhibition of AK reduced renal inflammation and oxidative stress in MLDS-induced diabetes, allowing the speculation that these effects were due to an increase of adenosine [117]. A downregulation of AK was observed in MLDS-diabetes, that was restored following insulin treatment [69,118]. This effect was found to be associated with inhibition of T lymphocytes proliferation [69].

    View all citing articles on Scopus
    1

    To whom correspondence should be addressed. Fax: (58) 344-9653. E-mail: [email protected].

    View full text